Company Overview and News
The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
Emmerson Resources Ltd (ASX:ERM) managing director & CEO Rob Bills visits the Proactive Investors Perth studio to discuss the just-announced Strategic Alliance with Territory Resources (ASX:TTY) at the Tennant Creek gold projects in Australia's Northern Territory.
Emmerson Resources Limited (ASX:ERM) is expecting news of a proposed mining and exploration joint venture agreement at its Tennant Creek projects in the Northern Territory and has been granted a trading halt.
ASXFF ASXFY ERM EMMRF
Emmerson Resources Ltd (ASX:ERM) managing director & CEO Rob Bills updates Proactive Investors on geochemistry sampling results and upcoming milestones at the company’s Whatling Hill discovery within the Fifield project in NSW, Australia.
Emmerson Resources Ltd (ASX:ERM) has received encouraging copper and gold geochemical results at its Whatling Hill Copper Gold prospect within the Fifield Project in New South Wales.
Emmerson Resources Limited (ASX:ERM) substantial shareholder Noontide Investments Ltd has increased its holding to 14.8% from 13.5% through a series of on-market transactions.
Emmerson Resources Ltd (ASX:ERM) managing director Rob Bills speaks to Proactive Investors about the latest news from the Tennant Creek Mineral Field, in Australia's Northern Territory. The explorer and producer holds a lot of land in the area, with a number or projects at various stages of development, from early-stage surveying work through to gold bar production.
Emmerson Resources Ltd (ASX:ERM) has received results from initial drilling at Mauretania within the Tennant Creek Mineral Field (TCMF) in the Northern Territory.
Emmerson Resources Limited (ASX:ERM) has received encouraging results from the first pass fieldwork at the Whatling Hill copper-gold prospect within its Fifield project in New South Wales.
NCMGF NCM NCMGY EVN AMI RRL 3993 CAHPF ERM RGRNF EMMRF
Emmerson Resources Ltd (ASX:ERM) managing director Rob Bills tells Proactive Investors about the explorer and producer's discovery of what could be a large porphyry copper system at Whatling Hill; part of the Fifield Project, which in turn is part of the company's exploration portfolio in NSW, Australia.
Emmerson Resources Ltd (ASX:ERM) managing director Rob Bills tells Proactive Investors about the explorer and producer's discovery of what could be a large porphyry copper system at Wattling Hill; part of the Fifield Project, which in turn is part of the company's exploration portfolio in NSW, Australia.
Emmerson Resources Ltd (ASX:ERM) managing director Rob Bills tells Proactive Investors all the details of the explorer and producer's recent agreement with Territory Resources Ltd (ASX:TTY).
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:ERM / EMMERSON RESOURCES LIMITED on message board site Silicon Investor.